Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection.

ABSTRACT:

Objective

To determine the effect of statins on the progression of subclinical atherosclerosis in a population of HIV-infected adults on antiretroviral therapy.

Design

Double-blind, randomized clinical trial.

Methods

Stopping Atherosclerosis and Treating Unhealthy Bone with RosuvastatiN in HIV infection was a 96-week double-blind, randomized clinical trial of 10 mg daily rosuvastatin (n = 72) vs. placebo (n = 75) in a population of HIV-infected subjects on stable antiretroviral therapy with LDL-cholesterol 130 mg/dl or less (≤3.36 mmol/l) and evidence of heightened T-cell activation (CD8CD38HLA-DR ≥19%) or increased inflammation [high sensitivity C-reactive protein ≥2 mg/l (≥19 mmol/l)]. Change in common carotid artery intima-media thickness (IMT) (CCA-IMT) was the pr

SUBMITTER: Longenecker CT 

PROVIDER: S-EPMC5007142 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature